PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29167337-13	2018	These findings indicate that the immunodominant HLA-B*27:02-restricted Nef response adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV CD8+ T-cell activity in HLA-B*27:05-positive subjects.	Glycosaminoglycans	119-122	CD8a molecule	Homo sapiens	168-171	
26291824-6	2015	In addition, Gag-stimulated CD8+ T-cells and cytokine-stimulated NK cells were tested for cytotoxic activity.	Glycosaminoglycans	13-16	CD8a molecule	Homo sapiens	28-31	
27427877-8	2016	Increases in CD4 and CD8 T-cell activation markers (P = 0.08 and P < 0.001, respectively) and HIV-specific CD8 responses (P = 0.04 for p24 gag, P = 0.01 for p17 gag and P = 0.04 for total gag) were seen in vaccinees but not controls.	Glycosaminoglycans	142-145	CD8a molecule	Homo sapiens	21-24	
26269189-13	2015	HIV controllers maintain a large proportion of Gag-specific expandable memory CD8(+) T cells involved in ongoing viral suppression.	Glycosaminoglycans	47-50	CD8a molecule	Homo sapiens	78-81	
28333940-0	2017	Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by SIVDeltanef live attenuated vaccine.	Glycosaminoglycans	35-38	CD8a molecule	Homo sapiens	48-51	
28333940-5	2017	We found that gene expression profiles of Gag-specific CD8+ T cells at 20 WPV are qualitatively different from those at 3 WPV.	Glycosaminoglycans	42-45	CD8a molecule	Homo sapiens	55-58	
28333940-6	2017	At 20 WPV, the most significant transcriptional changes of Gag-specific CD8+ T cells were genes involved in TCR signaling, differentiation and maturation toward central memory cells, with increased expression of CCR7, TCRalpha, TCRbeta, CD28 and decreased expression of CTLA-4, IFN-gamma, RANTES, granzyme A and B.	Glycosaminoglycans	59-62	CD8a molecule	Homo sapiens	72-75	
27829019-6	2016	The expression of PD-1 and PD-L1 was higher on Gag-specific CD8+ T cells as compared to CEF-specific CD8+ T cells, and the expression of these markers did not change significantly after Treg depletion or co-culture with Treg/HIV-, unlike on CEF-specific CD8+ T cells.	Glycosaminoglycans	47-50	CD8a molecule	Homo sapiens	60-63	
27711228-14	2016	In these 2, transient decreases in viremia were associated with Gag selection in known CD8+ T cell epitopes.	Glycosaminoglycans	64-67	CD8a molecule	Homo sapiens	87-90	
24010680-10	2014	These data support earlier studies suggesting that increased breadth of the Gag-specific CD8(+) T cell response may contribute to improved HIV immune control irrespective of the particular HLA molecules expressed.	Glycosaminoglycans	76-79	CD8a molecule	Homo sapiens	89-92	
26344746-12	2014	In the HIV-infected adults, increased CD8+ T-cell responses to Gag, RT and viral protease peptides were detected.	Glycosaminoglycans	63-66	CD8a molecule	Homo sapiens	38-41	
24371068-2	2014	Here, we investigated the reversion kinetics of Gag(181-189)CM9 CD8(TL) escape-associated compensatory mutations in simian immunodeficiency virus (SIV)-infected macaques.	Glycosaminoglycans	48-51	CD8a molecule	Homo sapiens	64-67	
23374084-5	2013	The majority of Gag-specific T-cell responses in the female genital tract were monofunctional, although low frequencies of HIV Gag-specific polyfunctional CD8(+) T cells were detected at the cervix in 81 3% (13/16) of women.	Glycosaminoglycans	127-130	CD8a molecule	Homo sapiens	155-158	
24505475-8	2014	Thus failure of gag ubiquitination to enhance CD8 responses may be caused by suppression of moDC maturation.	Glycosaminoglycans	16-19	CD8a molecule	Homo sapiens	46-49	
24416431-11	2014	In contrast, patients with high RAC to both Env and Gag (n = 8) had higher annual CD4 loss (p = 0.034) and lower CD8 counts (p = 0.014).	Glycosaminoglycans	52-55	CD8a molecule	Homo sapiens	113-116	
23374084-6	2013	The ability of CD8(+) T cells at both the cervix and in blood to express CD107a and to exhibit polyfunctional responses (two or more functions) following Gag stimulation was inversely associated with plasma viral load and positively associated with blood CD4 counts, suggesting that clinical status impacted on the functionality of HIV-specific T cells at the mucosa, in a similar way to blood.	Glycosaminoglycans	154-157	CD8a molecule	Homo sapiens	15-18	
23616666-0	2013	Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment.	Glycosaminoglycans	6-9	CD8a molecule	Homo sapiens	117-120	
23616666-11	2013	All together, this study underscores the importance of CD8(+) T-cell specificity in the improved control of disease progression, which was related to the capacity of Gag-specific cells to mediate both lytic and nonlytic antiviral mechanisms at early time points postinfection.	Glycosaminoglycans	166-169	CD8a molecule	Homo sapiens	55-58	
21994463-5	2011	Here, we used pyrosequencing to investigate the kinetics and patterns of mutations surrounding the Mamu-A1*00101-bound Gag(181-189)CM9 CD8+ T cell epitope.	Glycosaminoglycans	119-122	CD8a molecule	Homo sapiens	135-138	
22491464-9	2012	Gag-specific CD8(+) T-cell responses were efficiently induced in A(+) animals, while Nef-specific CD8(+) T-cell responses were in A(+), E(+), and B(+) animals.	Glycosaminoglycans	0-3	CD8a molecule	Homo sapiens	13-16	
22419810-8	2012	Remarkably, both the frequency and the number of Gag CM9-specific public clonotypes were strongly correlated with VIA mediated by EM CD8(+) T cells.	Glycosaminoglycans	49-52	CD8a molecule	Homo sapiens	133-136	
22377305-5	2012	A striking feature is the very efficient and polyfunctional CD8 T cell response of these patients, which exhibits a high avidity against the gag protein of the virus.	Glycosaminoglycans	141-144	CD8a molecule	Homo sapiens	60-63	
21778119-5	2011	The majority of Gag-responsive CD8 T cells were CD103+ in both blood and at the cervix.	Glycosaminoglycans	16-19	CD8a molecule	Homo sapiens	31-34	
21778119-6	2011	Despite this, the magnitude of Gag-specific IFN-gamma responses by CD103+CD8+ T cells in blood did not predict similar Gag-specific responses at the cervix.	Glycosaminoglycans	31-34	CD8a molecule	Homo sapiens	73-76	
21467219-5	2011	DEC-HIV Gag p24 showed better cross-priming for CD8(+) T cells, whereas the avidity of anti-Gag antibodies was ~10-fold higher with nontargeted Gag 24 protein.	Glycosaminoglycans	8-11	CD8a molecule	Homo sapiens	48-51	
21865377-4	2011	The CD4(+) T cell responses were predominantly Env directed, whereas the CD8(+) T cell responses were similarly distributed against Env, Gag, and GPN.	Glycosaminoglycans	137-140	CD8a molecule	Homo sapiens	73-76	
21159859-6	2011	Our data also reveal a direct relationship of gag and tat transcripts with CD4 and CD8 T cell activation, respectively.	Glycosaminoglycans	46-49	CD8a molecule	Homo sapiens	83-86	
21483689-9	2011	Lymph nodes contained increased numbers of Tregs as compared to peripheral blood, which positively correlated with gp120 levels; T regulatory cell depletion restored CD8 T cell responses to Gag but not to gp120.	Glycosaminoglycans	190-193	CD8a molecule	Homo sapiens	166-169	
21108465-0	2010	Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.	Glycosaminoglycans	15-18	CD8a molecule	Homo sapiens	28-31	
21818255-10	2011	The differentiation profiles and multifunctionality of Gag-specific CD8+ T cells, regardless of immunodominance, also failed to demonstrate meaningful differences between the two groups.	Glycosaminoglycans	55-58	CD8a molecule	Homo sapiens	68-71	
19605475-1	2009	A broad Gag-specific CD8(+) T-cell response is associated with effective control of adult human immunodeficiency virus (HIV) infection.	Glycosaminoglycans	8-11	CD8a molecule	Homo sapiens	21-24	
20561662-4	2010	At the time of superinfection, its plasma was unable to efficiently neutralize the superinfecting virus and moderate Gag-specific CD8(+) T-cell responses were observed.	Glycosaminoglycans	117-120	CD8a molecule	Homo sapiens	130-133	
19641002-4	2009	Infection of vaccinated Mamu-A*01(+) rhesus monkeys with a SHIV Gag Deltap11C mutant virus generated a significantly increased expansion of the Env p41A-specific CD8(+) T-lymphocyte response in the absence of secondary Gag p11C-specific CD8(+) T-lymphocyte responses.	Glycosaminoglycans	64-67	CD8a molecule	Homo sapiens	162-165	
19641002-4	2009	Infection of vaccinated Mamu-A*01(+) rhesus monkeys with a SHIV Gag Deltap11C mutant virus generated a significantly increased expansion of the Env p41A-specific CD8(+) T-lymphocyte response in the absence of secondary Gag p11C-specific CD8(+) T-lymphocyte responses.	Glycosaminoglycans	64-67	CD8a molecule	Homo sapiens	237-240	
20668079-10	2010	Taken together, these findings demonstrate that (i) Gag-specific responses dominate in mucosal tissues of HIV controllers; (ii) there is extensive overlap between CD8(+) T cells in blood and mucosal tissues, with responses to immunodominant epitopes generally shared by both sites; and (iii) mucosal T-cell response breadth alone cannot account for immune control.	Glycosaminoglycans	52-55	CD8a molecule	Homo sapiens	163-166	
19910798-2	2010	In the 2 subjects who exhibited the best viral control, we detected CD8(+) T-cell responses against 1-2 Gag epitopes during the early weeks of TI and a subsequent increase in the number of epitopes recognized by the later time points.	Glycosaminoglycans	104-107	CD8a molecule	Homo sapiens	68-71	
19605475-7	2009	Slow progressors tended to make CD8(+) T-cell responses to Gag epitopes presented by the protective HLA-B alleles, in contrast to progressors expressing the same alleles (P = 0.07; Fisher"s exact test).	Glycosaminoglycans	59-62	CD8a molecule	Homo sapiens	32-35	
19494307-11	2009	These results, on the one hand, suggest the importance of Gag responses in the antiviral potency of CD8(+) T cells from HICs and, on the other hand, propose that other host mechanisms may contribute to restraining HIV infection in HICs.	Glycosaminoglycans	58-61	CD8a molecule	Homo sapiens	100-103	
18008010-5	2007	rAAV vector-induced CD8(+) T cells proliferated poorly, produced low levels of IFN-gamma in response to gag stimulation, and upregulated immunoinhibitory molecules.	Glycosaminoglycans	104-107	CD8a molecule	Homo sapiens	20-23	
18788910-4	2008	Production of MIP-1beta, IL-2, TNF-alpha, and CD107 expression by CD8(+) T cells in response to Gag and Nef optimal peptide pools was analyzed using polychromatic flow cytometry in nine HIV-infected individuals followed for 12 months after discontinuation of antiretroviral therapy.	Glycosaminoglycans	96-99	CD8a molecule	Homo sapiens	66-69	
18275276-4	2008	RESULTS: CD8+ T cells from both controller groups preferentially target Gag over other proteins in the context of diverse HLA class I alleles, whereas responses are more broadly distributed in persons with progressive infection.	Glycosaminoglycans	72-75	CD8a molecule	Homo sapiens	9-12	
19428572-2	2009	Development of novel and effective Gag-targeted vaccine candidates inducing CD8(+) and CD4(+) T cell responses requires large scale pre-clinical testing in a small animal model.	Glycosaminoglycans	35-38	CD8a molecule	Homo sapiens	76-79	
18974782-4	2008	In subjects not on ART, the percentage of rectal Gag-specific CD8+ T-cells capable of 3, 4 or 5 simultaneous effector functions was significantly related to blood CD4 count and inversely related to plasma viral load (PVL) (p<0.05).	Glycosaminoglycans	49-52	CD8a molecule	Homo sapiens	62-65	
18974782-9	2008	CONCLUSIONS: The polyfunctionality of rectal Gag-specific CD8+ T-cells appears to be related to blood CD4 count and inversely related to PVL.	Glycosaminoglycans	45-48	CD8a molecule	Homo sapiens	58-61	
17699580-2	2007	We have recently shown that Gag-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells at 2 h postinfection, whereas Env-specific CD8+ T cells do not recognize infected cells until much later in infection.	Glycosaminoglycans	28-31	CD8a molecule	Homo sapiens	41-44	
17893201-2	2007	We report that CD8+ T cell responses specific for Gag and, in particular, the immunodominant p24 epitope KK10 correlate with control of HIV-1 replication in human histocompatibility leukocyte antigen (HLA)-B27 patients.	Glycosaminoglycans	50-53	CD8a molecule	Homo sapiens	15-18	
17878372-3	2007	The ratio of Bcl-2+ Gag-specific CD8+ T cells to caspase-3+ Gag-specific CD8+ T cells was higher in the vaccinated-protected animals compared with unprotected monkeys.	Glycosaminoglycans	20-23	CD8a molecule	Homo sapiens	33-36	
16763520-0	2006	Correlation between gag-specific CD8 T-cell responses, viral load, and CD4 count in HIV-1 infection is dependent on disease status.	Glycosaminoglycans	20-23	CD8a molecule	Homo sapiens	33-36	
17615585-5	2007	Rhesus DC transfected with lysosome-targeted gag encoding an escape mutation in an immunodominant CTL epitope stimulated CD4+ and CD8+ T cell responses of almost equivalent magnitude directed towards undefined epitopes outside of the mutated region.	Glycosaminoglycans	45-48	CD8a molecule	Homo sapiens	130-133	
16989614-0	2006	Impact of Gag sequence variability on level, phenotype, and function of anti-HIV Gag-specific CD8(+) cytotoxic T lymphocytes in untreated chronically HIV-infected patients.	Glycosaminoglycans	10-13	CD8a molecule	Homo sapiens	94-97	
16971807-4	2006	These cells not only express and secrete the HIV p24 antigen after electroporation with codon-optimized HIV-1 gag mRNA, but can also be used to in vitro reactivate Gag antigen-specific interferon-gamma-producing CD4 and CD8 autologous T-cells.	Glycosaminoglycans	164-167	CD8a molecule	Homo sapiens	220-223	
17344302-9	2007	In patients not on antiretroviral therapy, the magnitude of Gag-specific responses, as a percentage of CD8(+) T cells, was greater in the rectal mucosa than in PBMC (P = 0.054); however, the breakdown of responding cells into specific functional categories was similar in both sites.	Glycosaminoglycans	60-63	CD8a molecule	Homo sapiens	103-106	
17376899-2	2007	Following infection, the majority (>95%) of Gag-specific CD8 T cells expressed PD-1, and the level of PD-1 expression per cell increased over time.	Glycosaminoglycans	47-50	CD8a molecule	Homo sapiens	60-63	
17344296-6	2007	A transient CD8(+) cell depletion experiment 3 years postinfection resulted in transient reappearance of plasma viremia in these two animals, suggesting involvement of the SIV non-Gag-specific CTLs in the chronic SIV control.	Glycosaminoglycans	180-183	CD8a molecule	Homo sapiens	12-15	
17344299-0	2007	In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques.	Glycosaminoglycans	35-38	CD8a molecule	Homo sapiens	39-42	
17030874-3	2006	The generation of Gag-specific CD8(+) T cells was reported previously from a cynomolgus monkey infected with SHIV89.6P by taking advantage of a B-lymphoblastoid cell line transduced with a retroviral vector expressing simian immunodeficiency virus (SIV) Gag.	Glycosaminoglycans	18-21	CD8a molecule	Homo sapiens	31-34	
16763520-10	2006	Gag-specific CD8 responses may play differential roles in different stages of HIV-1 infection, and the maintenance of a threshold level of CD4 T-cells may contribute to mediate effective HIV-specific responses in natural control of HIV-1 infection.	Glycosaminoglycans	0-3	CD8a molecule	Homo sapiens	13-16	
16406047-4	2006	However, one pediatric subject with late-stage infection displayed robust expansion of Gag 77-85-specific CD8 T cells which were perforin+ and lytic, but lacked expression of CD27 and IFNgamma.	Glycosaminoglycans	87-90	CD8a molecule	Homo sapiens	106-109	
15580653-4	2005	The circulating gag-specific CD8(+) T cells in fresh blood reliably produced IFN-gamma but lacked IL-2 and high perforin levels and failed to expand significantly during culture with mature DC presenting HIV-1 gag peptides.	Glycosaminoglycans	16-19	CD8a molecule	Homo sapiens	29-32	
16282500-0	2005	Tat(28-35)SL8-specific CD8+ T lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay.	Glycosaminoglycans	66-69	CD8a molecule	Homo sapiens	91-94	
15680145-2	2005	Here, we screen a cohort of HIV-1-infected persons in the United States for CD8+ T lymphocyte (CTL) responses using Gag peptides based on the Clade C primary isolate DU422 and the consensus sequence for Clade B.	Glycosaminoglycans	116-119	CD8a molecule	Homo sapiens	76-79	
33072082-3	2020	CD160+ CD8+ T cells derived from HIV+ patients correlated with slow progressions both in a cross-sectional study and in a 60-month longitudinal cohort, displaying enhanced cytotoxicity and proliferative capacity in response to HIV Gag stimulation; triggering CD160 promoted their functionalities through MEK-ERK and PI3K-AKT pathways.	Glycosaminoglycans	231-234	CD8a molecule	Homo sapiens	7-10	
14980480-5	2004	Gag-specific CD8+ T-cells were found in separated IELs from the rectum, colon, jejunum, and vagina of most infected animals.	Glycosaminoglycans	0-3	CD8a molecule	Homo sapiens	13-16	
11739667-5	2002	The percentage of Gag-specific, tetramer-positive T cells was as high as 13 to 14% of the CD3+ CD8+ T-cell population in the vaginal and cervical laminae propriae of both SIVmac251 and SHIV(KU2) chronically infected macaques.	Glycosaminoglycans	18-21	CD8a molecule	Homo sapiens	95-98	
34686680-6	2021	The SHIV-Ag85B-inoculated macaques showed enhancement of Gag-specific monofunctional and polyfunctional CD8+ T cells in the acute phase of the pathogenic SHIV challenge.	Glycosaminoglycans	57-60	CD8a molecule	Homo sapiens	104-107	
34369597-0	2021	Clonotypic architecture of a Gag-specific CD8+ T-cell response in chronic human HIV-2 infection.	Glycosaminoglycans	29-32	CD8a molecule	Homo sapiens	42-45	
34369597-3	2021	To address this question, we undertook a detailed molecular characterization of the clonotypic architecture of an HLA-B*3501 restricted Gag -specific CD8+ T-cell response in donors chronically infected with HIV-2 using a combination of flow cytometry, tetramer-specific CD8+ TCR clonotyping and in vitro assays.	Glycosaminoglycans	136-139	CD8a molecule	Homo sapiens	150-153	
34369597-3	2021	To address this question, we undertook a detailed molecular characterization of the clonotypic architecture of an HLA-B*3501 restricted Gag -specific CD8+ T-cell response in donors chronically infected with HIV-2 using a combination of flow cytometry, tetramer-specific CD8+ TCR clonotyping and in vitro assays.	Glycosaminoglycans	136-139	CD8a molecule	Homo sapiens	270-273	
33859108-9	2021	P2 demonstrated a striking increase in the frequency of gag-specific central and effector memory CD8+ T cells producing IFN-gamma, TNF-alpha, and CD107a following anti-PD1 and anti-CTLA-4.	Glycosaminoglycans	56-59	CD8a molecule	Homo sapiens	97-100	
32979832-5	2020	However, this protective effect diminished quickly after seven days, followed by a rapid reduction of GAG-specific CD8+T cell number and activity, and viral persistence.	Glycosaminoglycans	102-105	CD8a molecule	Homo sapiens	115-118	
14741150-2	2004	The CD8+ T-cell response to the dominant Gag(181-189) CM9 was quantitated in seven Mamu-A*01-positive macaques by tetramer staining, by ex vivo cytotoxic T-lymphocyte (CTL) activity, and by intracellular cytokine staining (ICS) with the specific Gag(181-189) CM9 peptide.	Glycosaminoglycans	41-44	CD8a molecule	Homo sapiens	4-7	
14741150-3	2004	The overall CD8+ T-cell response to Gag was assessed using a peptide pool encompassing the entire Gag protein followed by measurement of TNF-alpha production in ICS assay.	Glycosaminoglycans	36-39	CD8a molecule	Homo sapiens	12-15	
14741150-3	2004	The overall CD8+ T-cell response to Gag was assessed using a peptide pool encompassing the entire Gag protein followed by measurement of TNF-alpha production in ICS assay.	Glycosaminoglycans	98-101	CD8a molecule	Homo sapiens	12-15	
14662882-6	2003	This vector, which belongs to a different serotype than the AdC68 virus, induces high frequencies of gag-specific CD8(+) T cells in mice including those pre-exposed to AdHu5 virus.	Glycosaminoglycans	101-104	CD8a molecule	Homo sapiens	114-117	
12682278-4	2003	Furthermore, subjects with a severely depleted and phenotypically altered CD4(+) T cell compartment had circulating Gag-specific CD8(+) T cells with impaired IFN-gamma production.	Glycosaminoglycans	116-119	CD8a molecule	Homo sapiens	129-132	
12444145-10	2002	The Gag-specific IFN-gamma(+)IL-2(+) CD4 response also correlated positively with the percentage of Gag-specific IFN-gamma(+) CD8 T cells in these subjects.	Glycosaminoglycans	4-7	CD8a molecule	Homo sapiens	126-129	
12351944-8	2002	The percentage of HIV-specific CD8 T cells also significantly correlated with the percentage of Gag-specific cytotoxicity measured by the traditional Cr release assay.	Glycosaminoglycans	96-99	CD8a molecule	Homo sapiens	31-34	
11595301-6	2001	Although similar frequencies of Gag peptide-specific CD8(+) T cells were found in LTNP and progressors by either intracellular IFN-gamma or MHC class I tetramer staining, the breadth of these responses was greater in patients with progressive HIV infection compared with the LTNP group.	Glycosaminoglycans	32-35	CD8a molecule	Homo sapiens	53-56	
16622001-5	2006	We observed that vaccination was associated with the preservation of Gag-specific central memory CD8(+) T cells that were functionally capable of producing IFN-gamma, and effector memory CD8(+) T cells that were capable of producing granzyme B following viral Ag exposure.	Glycosaminoglycans	69-72	CD8a molecule	Homo sapiens	97-100	
34280415-7	2021	Moreover, sHDL-Gag + polyICLC induced robust Simian immunodeficiency virus Gag-specific, polyfunctional CD8+ T cell responses in rhesus macaques and could further amplify the efficacy of recombinant adenovirus-based vaccine.	Glycosaminoglycans	15-18	CD8a molecule	Homo sapiens	104-107	
35231604-3	2022	We have recently developed an immunogen (CaV11), tandemly connected overlapping 11-mer peptides spanning the simian immunodeficiency virus (SIV) Gag capsid and Vif proteins, to selectively induce Gag- and Vif-specific CD8+ T cells but not CD4+ T cells.	Glycosaminoglycans	196-199	CD8a molecule	Homo sapiens	218-221	
34581306-5	2022	The HIV-specific T-cell responses among PECs were characterized by high-frequency Gag-specific CD4+ T-cell activity, and markedly more polyfunctional Gag-specific CD8+ activity, compared with PNPs and progressors.	Glycosaminoglycans	150-153	CD8a molecule	Homo sapiens	163-166	
33328567-7	2020	Specifically, superior sustained systemic and mucosal HIV Gag-specific poly-functional/cytotoxic CD4+ and CD8+ T cells were detected with the IL-4R antagonist adjuvanted strategy compared to the unadjuvanted control.	Glycosaminoglycans	58-61	CD8a molecule	Homo sapiens	106-109	
31301135-4	2019	Along those lines, vaccine recipients with higher HLA-I adaptation to the Gag vaccine insert mounted less polyfunctional CD8 T-cell responses at the protein-level.	Glycosaminoglycans	74-77	CD8a molecule	Homo sapiens	121-124	
31661461-5	2020	Rhesus macaques with low viral loads (VLs) harbored higher frequencies of polyfunctional CXCR5+ SIV-specific CD8+ T cells in various lymphoid tissues and higher proportions of unique Gag-specific CD8+ T cell clonotypes in the mesenteric lymph nodes relative to rhesus macaques with high VLs.	Glycosaminoglycans	183-186	CD8a molecule	Homo sapiens	196-199	
31661461-6	2020	In addition, public Gag-specific CD8+ T cell clonotypes were more commonly shared across distinct anatomical sites than the corresponding private clonotypes, which tended to form tissue-specific repertoires, especially in the peripheral blood and the gastrointestinal tract.	Glycosaminoglycans	20-23	CD8a molecule	Homo sapiens	33-36	
32647227-0	2020	Therapeutic vaccine-mediated Gag-specific CD8+ T-cell induction under anti-retroviral therapy augments anti-virus efficacy of CD8+ cells in simian immunodeficiency virus-infected macaques.	Glycosaminoglycans	29-32	CD8a molecule	Homo sapiens	42-45	
32647227-0	2020	Therapeutic vaccine-mediated Gag-specific CD8+ T-cell induction under anti-retroviral therapy augments anti-virus efficacy of CD8+ cells in simian immunodeficiency virus-infected macaques.	Glycosaminoglycans	29-32	CD8a molecule	Homo sapiens	126-129	
32647227-8	2020	In the vaccinated animals, the anti-SIV efficacy of CD8+ cells at week 34 was correlated positively with Gag-specific CD8+ T-cell frequencies and inversely with rebound viral loads at week 34.	Glycosaminoglycans	105-108	CD8a molecule	Homo sapiens	52-55	
32647227-8	2020	In the vaccinated animals, the anti-SIV efficacy of CD8+ cells at week 34 was correlated positively with Gag-specific CD8+ T-cell frequencies and inversely with rebound viral loads at week 34.	Glycosaminoglycans	105-108	CD8a molecule	Homo sapiens	118-121	
31106390-0	2019	Correction to: Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate gag-specific memory CD8+ T cells ex vivo.	Glycosaminoglycans	124-127	CD8a molecule	Homo sapiens	144-147	
30564243-6	2018	In vitro study shows that IL-33 promotes the expression of IFN-gamma by Gag stimulated CD4+ and CD8+T cells from HIV-infected patients to a certain extent.	Glycosaminoglycans	72-75	CD8a molecule	Homo sapiens	96-99	
31034775-6	2019	In addition, CCR5 is highly expressed on SIV gag-specific (CM9+) CD8+ T cells in SIV-infected macaques, yet CCR5+CD8+ T cells are significantly reduced in mucosal lymphoid tissues with disease progression.	Glycosaminoglycans	45-48	CD8a molecule	Homo sapiens	65-68	
30921340-8	2019	It was observed that DNA priming and MVA boosting induced Env and Gag specific bi-functional and multi-functional CD4+ and CD8+ T cells expressing IFN-gamma, TNF-alpha and IL-2.	Glycosaminoglycans	66-69	CD8a molecule	Homo sapiens	123-126	
30830870-4	2019	Immunization with HVVs induced very high-magnitude Gag-specific CD8+ T cell responses in blood and tissue-resident CD8+ memory T cells in vaginal mucosa.	Glycosaminoglycans	51-54	CD8a molecule	Homo sapiens	64-67